Gene expression signatures predict first-year response to somapacitan treatment in children with GH deficiency.

Pre-treatment transcriptome predicts first-year growth response in somapacitan-treated children with GHD. A common set of genes can predict the treatment response to both once-weekly somapacitan and conventional daily GH. This approach could potentially be developed into a clinically-applicable pre-treatment test to improve clinical management.